Anti-IgE antibody

This brief review summarizes the rationale for selecting IgE as a target ap propriate for specific therapy, the development and preclinical testing of a selective monoclonal anti-IgE antibody, the demonstration of its safety a nd efficacy in a clinical model, and, finally, the demonstration of the ant ibody's safety and efficacy in a large clinical trial.